This article features executive conversations with two AWS Generative AI Accelerator startups—Nosis Bio and Vevo—discussing how they apply generative AI to pharmaceutical R&D.

• Nosis Bio uses generative AI to design Targeted Delivery Vehicles for precision drug delivery to diseased tissues
• Vevo combines organoid/in vivo models with AI to discover drugs by understanding gene function in disease context
• Both companies emphasize rigorous validation and biological testing to separate hype from genuine innovation
• AWS provides compute resources, cloud infrastructure, and bioinformatics expertise to optimize model training
• Key success drivers: interdisciplinary collaboration between data scientists and wet lab researchers
• Generative AI will accelerate all pharma R&D stages from target selection through drug development
• Startups must choose models wisely and build custom models for specialized applications like drug discovery

The conversation highlights how generative AI is transforming drug discovery when combined with rigorous scientific validation and high-quality biological data.